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ABSTRACT

Gram-negative bacteria use acyl-homoserine lactone (AHL) based quorum
sensing (QS) to regulate the expression of genes that give the bacteria a selective
advantage over host defenses and antibiotic treatment. Burkholderia mallei is an
antibiotic resistant pathogen that causes Glanders disease. B. mallei BmaI1 AHLsynthase uses octanoyl-Acyl Carrier Protein (C8ACP) and S-adenosyl-L-methionine
(SAM) to synthesize the AHL, octanoyl-homoserine lactone (C8HSL). Inhibiting AHLsynthases has been difficult because mechanistic and substrate specificity details for these
enzymes are not well understood. Our goal was to determine how BmaI1 activity and
enzymatic mechanism changes with nonspecific, variable acyl chain acyl-ACP substrates.
We found that catalytic efficiency of nonspecific acyl-ACP substrates are drastically low
compared to the native C8ACP substrate, in-line with tight signal specificity observed in
vivo. In addition, substrates with lower catalytic efficiency also showed kinetic
cooperativity while reacting with BmaI1. Our results suggest that substrates add by a
preferred order, random sequential mechanism to BmaI1. Alternatively, BmaI1 could
exist in two forms, where nonspecific substrates bind to the less active enzyme form and
leads to the formation of an unproductive E.acyl-ACP complex. Apparently, only the
native acyl-ACP substrate forms both a stable and productive E.acyl-ACP complex, thus
providing a molecular basis for substrate discrimination in QS signal synthesis in B.
mallei.
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CHAPTER ONE: INTRODUCTION

Quorum Sensing
Quorum sensing (QS) is a type of bacterial intercellular communication that
occurs at high cell population densities.1 QS coordinates bacterial behaviors so as to
function like a multicellular organism. The behaviors governed by QS are those that
when attempted by individual cells are unproductive, however, when attempted by the
masses provide an evolutionary advantage.2,3 The chemical signal molecules responsible
for QS are diffusible, low molecular weight (c. 170-300 Da) pheromones referred to as
autoinducers (AIs).4 QS is achieved through the accumulation of AIs that enable
individual cells to sense when the minimal population unit or “quorum” of bacteria has
been achieved for a concerted population response to be initiated.4
The regulatory components and molecular mechanisms of QS differ among
bacterial species. Nonetheless, there are three basic principles that apply to all cases of
QS. First, all communicating bacteria produce AIs. When there is a low population
within a bacterial community, the AIs synthesized are in such low concentration that they
are unable to stimulate a population-wide response. Once a population reaches high
density, the cumulative amount of AIs produces a global response. The second principle
of QS is that receptors for AIs exist in the membrane or in the cytoplasm of the
responding cells. AIs secreted from one cell bind to neighboring bacteria. Lastly, AIs
induce the expression of a variety of genes that can stimulate production of additional AIs
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through a positive feedback loop to sponsor synchronous behavior in the cell population
(Fig. 1).5

Figure 1.
General scheme of a QS system. The signal synthase enzyme produces
signal molecules (AIs), which diffuse or are transported to the extracellular environment.
At an optimal concentration of the signal, the AI binds to the receptor, which can be
located in the cytoplasm (A) or at the cell surface (B). If the receptor is located in the
cytoplasm, the AI-receptor complex activates or inactivates the transcription of target
genes. When the receptor is located at the cell surface, the signal induces a
phosphorylation signal transduction cascade. This activates a transcriptional regulator
that leads to targeted gene transcription.5
QS was discovered 30 years ago in two light-producing bacterial species, Vibrio
fisheri and Vibrio harveyi.1,2 These bacteria emitted light at high cell population density,
when the accumulation of secreted AIs stimulated the expression of the structural operon
luxCDAB.6,7 This operon encodes the light producing luciferase enzyme. Today, QS has
been observed in both Gram-negative and Gram-positive bacteria though the mechanism
of QS differs.
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Table 1.

Classification of QS autoinducer molecules

Gram-positive bacteria use small cyclic peptides called autoinducer peptides
(AIP) as signaling molecules (Table 1).3,7 The AIPs are synthesized in the cytoplasm and
are actively transported out of the cell to interact with a two-component type extracellular
domain of membrane bound sensor receptors.6,7 The bound AIP initiates a
phosphorylation cascade that modulates the activity of a DNA-binding protein that
regulates transcription of target genes. This protein is termed a response regulator and is
highly selective for a given peptide signal.3,6,7 This selectivity allows the bacterial
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community to communicate efficiently. Gram-positive bacteria can use multiple AIs and
receptors in series or in parallel to achieve desired behaviors. One Gram-positive
bacteria, Staphylococcus aureus, synthesize AIPs to regulate the agr system that controls
more than 70 genes that are known to code for virulence factors.8
Quorum sensing in Gram-negative bacteria does not involve the use of AIPs. In
Gram-negative bacteria, small molecules known as acyl-homoserine-lactones (AHL/AI1) are used as QS signaling molecules (Table 1). QS in the V. fischeri sp. is the most
extensively studied system to date.9-12 Two regulatory proteins, LuxI and LuxR, are
responsible for biosynthesis of the AI and subsequent behavior of the bacteria. The AHL
diffuses across cell membranes and, at optimal concentrations, binds to the LuxR
receptor, which regulates the transcription of a multitude of genes. The Gram-negative
bacterium Pseudomonas aeruginosa produces two AHL signals to regulate more than
350 genes that regulate extracellular virulence factors, biofilm formation, and antibiotic
efflux pumps.13-15
In addition to the AIP and AI-1 systems, a universal signal molecule that allows
inter-species communication has also been observed.3,16 This signal molecule is AI-2
(Table 1). When AI-2 is bound to its receptor, a phosphorylation signal cascade is
initiated that influences the activity of a DNA-binding transcription protein.
Although AI-1, AI-2, and AIP signaling systems have been extensively studied,
other AI QS systems are known. These include the epinephrine-like AI structure (AI-3)
observed in E. coli O157:H7 that appears to regulate the formation of lesions as well as
the isoprenoid farnesol AI signal found in the yeast Candida albicans (Table 1).16-18 The
interest of the work herein concerns gram negative QS systems. Many of the genes
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transcribed by the QS molecules listed in Table 1 are those that lead to virulence, which
includes toxin release, biofilm formation, and resistance.

Biofilms and Resistance
Biofilms allow bacteria to exist within a community rather than being singly
dispersed in an environment. Communal existence is optimal for survival and therefore
the majority of bacteria in nature are found within biofilms. Biofilms can have one
species of bacteria or be a multi-species biofilm. Biofilms provide a safe environment for
survival and symbiotic relationships so that optimal microenvironments exist.19,20
Biofilm formation occurs when planktonic bacterial cells adhere to a surface and
an optimal cell density is reached so that AI molecules signal QS. The QS signaling
pathways lead to altered gene transcription to produce an exopolysaccharide matrix.21
This matrix envelops the micro-colony. Inside the micro-colony, further alteration of
genes produce a wide array of behaviors and phenotypes including attaining communal
existence of an individual bacterial cell and up-regulation of genes encoding enzymes,
transporters, and channels.19,22,23 The regulation of these genes produces a toxic and
hazardous environment for foreign invaders.
Biofilms are composed of a collection of bacterial cells that secrete the
polysaccharide matrix. This thick, sticky matrix acts as a shield against the host’s
immune response by preventing access to the entire micro-colony. Its depth limits both
phagocytosis by neutrophils and antibiotics intervention by preventing full eradication of
all the microbes in the community.24 Therefore, biofilms allow bacteria to become
resistant to the host’s immune defense as well as pharmacological intervention.

Over
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80% of bacterial infections in humans involve the formation of a biofilm.25,26 This has led
to research into targeting QS when developing therapeutics.

Quorum Sensing as a Drug Target
Multi-drug resistant bacteria pose major hurdles for antibacterial therapy. The
ability of bacteria to resist antibiotic treatment was first observed in the late 1930s-1950s
after the widespread dispersal of sulfonamides and penicillin.24,25 The majority of
antibacterial compounds work by killing the bacteria as a whole. Mutations in bacteria as
well as improper use of drugs allow the species to survive and adapt to subsequent
treatments, ideally becoming multi-drug resistant. Today, bacteria have the ability to gain
resistance to every antibiotic used in treating infections. Therefore, there is a need to
prevent multi-drug resistance from occurring when treating bacterial infections. One
such option is to target the QS system used by the bacteria. This would not kill the
bacteria as a whole, but would prevent the transcription of genes that lead to biofilms and
resistance. The host’s immune response should be able to then actively target the
infection and successfully kill the bacteria. This approach is advantageous over
conventional antimicrobial agents because (1) the likelihood for rapid mutations to occur
that develop drug resistance is low; (2) beneficial normal flora of the host is not killed;
(3) not immediately killing the bacteria may allow the host to mount a robust immune
response and therefore eliminate the infection without the need of bactericidal agents; and
(4) not immediately killing the bacteria would prevent the massive release of toxic
lipopolysaccharides associated with bacterial death, which often leads to sepsis.26
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Figure 2.
AHL-synthase substrate, AHL signal and bacterial phenotype. Over
70 gram negative bacterial species have been discovered to produce AHL. AHL lead to
phenotypic behavior that is virulent to the host.
Quorum sensing can be inhibited at one or more steps in QS pathways. In Gramnegative bacteria, the initiator and receptor proteins (LuxI/LuxR type) are targets for
inhibition. One option that has been explored is to design receptor inhibitors/antagonists,
which can bind to the AHL receptor but not elicit the subsequent biological response.26-28
Blackwell and coworkers have reported a number of AHL receptor antagonists that
showed biofilm inhibition activity.26-29 Most of these antagonists are designed as
modified AHLs. The modifications include acyl chain and/or the lactone ring variations
in the native AHL AI. Since multiple receptors are used to control QS in a cell, targeting
the receptor to inhibit QS is very difficult. In addition, AHL receptors bind to their
cognate AI with nanomolar affinities and therefore it is difficult to design ligands that
could outcompete these tight-binding native AHLs. Another option is to inhibit the
initiator protein to stop the AI from being generated at sufficient levels required for
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intercellular communication. This approach can prevent the biofilm from forming
because synthesis of the AHL signal would be insufficient to initiate a QS signal cascade.
In fact, studies involving P. aeruginosa null mutants that lack the LasI AHL synthase
show a decrease in biofilm formation and attenuated virulence.30 Although inhibition of
AHL synthesis is desirable to interrupt interbacterial communication, designing AHLsynthase inhibitors are not straightforward because the mechanism of AHL synthesis is
poorly understood. A key objective of this thesis is to address mechanistic questions on
Burkhloderia mallei BmaI1 AHL-synthase enzyme. We believe that a deeper
understanding of the mechanism of AHL synthesis will accelerate the discovery of QS
inhibitors.

AHL-synthase; BmaI1
In Gram-negative bacteria, the AHL-synthase enzyme responsible for making
AHL AI signal are most often members of the LuxI protein family and have sequence
similarity.30 There have been over 70 different AHL-synthases discovered to date that
produce specific AHL signal molecules (Fig. 2). These bacteria are pathogens to
humans, animals, plants, aquatic life, and more due to the LuxI/LuxR QS system. Some
examples of AHL-synthases known that lead to virulence factor expression include V.
fisheri LuxI AHL-synthase (aquatic pathogen), Agrobacterium tumefaciens TraI AHLsynthase (aquatic and human pathogen), Pantoea stewartii EsaI AHL-synthase (plant
pathogen), Pseudomonas aeruginosa LasI and RhlI AHL-synthase (human pathogen),
and the Burkholderia mallei BmaI1 AHL-synthase (animal and human pathogen). The
focus of this thesis is to address mechanistic questions on an AHL-synthase protein from
B. mallei, BmaI1.
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B. mallei was first isolated by William Schutz and Friedrich Loffler in 1882.31,32
B. mallei is an opportunistic, aerobic, animal, and human pathogen found in the air and
water. B. mallei infects by lysing entry vacuoles in the host’s cell. It gains motility once
inside the cell and can escape from cells during immune responses and antibacterial
defenses through use of multi-nucleated giant cells (MNCs).31 This motility and evasion
process lets the bacteria survive in the host longer, eventually forming a micro-colony
and becoming virulent to the host.
Glanders disease results from a B. mallei infection. Glanders is primarily a
disease affecting horses, but it also affects donkeys, mules, goats, dogs, cats, and
humans.31 Geographically, the disease is found in Africa, Asia, the Middle East, and
Central and South America. Animal infections are common in these areas, but human
infections have only occurred rarely and sporadically. Most human infections occurred
in laboratory workers and those in direct and prolonged contact with infected, domestic
animals. This bacterium has shown resistance to a number of antibiotics including
aminoglycosides, polymyxins, and beta-lactams. 31,32
Even though there is wide spread knowledge of B. mallei infections that result in
Glanders disease, there is little known about the enzymes responsible for the AHL
signaling. There are multiple BmaI-BmaR QS systems responsible for virulence found in
B. mallei including BmaI1-BmaR1, BmaI3-BmaR3, and the LuxR orphan proteins
BmaR4 and BmaR5. These systems use different acyl-ACPs to produce AHLs for a QS
response including octanoyl-ACP (C8ACP), 3-hydroxy-octanoyl-ACP (3-OH-C8-ACP),
hexanoyl-ACP (C6ACP), N-3-hydroxy-hexanoyl-ACP (3-OH-C6-ACP), and N-3hydroxy-decanoyl-ACP (N-3-OH-C10-ACP.32,33 Because pathogenic bacteria like B.
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mallei use AHL signals to regulate virulence genes, an understanding of the mechanism
of signal synthesis may lead to the development of QS-targeted anti-virulence molecules.

AHL-synthase Proposed Mechanism
AHLs are derived from S-adenosyl-L-methionine (SAM) and acyl-acyl-carrier
protein (acyl-ACP). The enzymes responsible for synthesizing AHLs are LuxI family
AHL-synthases.36,37 The proposed mechanism for synthesizing all AHLs (Fig. 3) suggests
that a general base in the AHL-synthase active site deprotonates the SAM-amine. The
nucleophilic SAM-amine attacks the carbonyl center on the acyl-ACP releasing holoACP. Lactonization of the SAM intermediate produces the AHL and
methylthioadenosine (MTA). BmaI1’s native acyl-ACP substrate is octanoyl-ACP
(C8ACP). When combined with SAM and C8ACP, this enzyme produces the QS AI
signal octanoyl-homoserine-lactone (C8HSL).33 BmaI1 is auto-regulated by the C8HSL
signal and the BmaR1 receptor.
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AHL-synthase Substrates

S-Adenosyl-L-Methionine (SAM)
SAM is synthesized in the cytosol by methionine adenosyl-transferase, which
joins L-methionine to ATP and yields SAM, pyrophosphate, and phosphate ion.33 SAM
is primarily a methyl group donor in methylation reactions of macromolecules and small
molecules. It is uniquely used with AHL-synthases not as a methyl donor but to form a
lactone ring in AHL product.
SAM is commercially available and frequently used when studying AHLsynthases. Commercially available samples of SAM formulations are most stable at
acidic pH and at lower temperatures.34 The purity of SAM varies due to the degradation
of SAM by cleavage into MTA and HSL and hydrolysis to adenine and S-(5`deoxyribosyl)-L-methionine. The products of this degradation are also products in the
AHL-synthase reaction (Fig. 4).34
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To improve SAM stability, commercially available formulations with larger
molecular weight salts were prepared. It is unknown whether these SAM-salts affect
AHL-synthase activity. SAM-salts formulations like SAM-Cl, SAM-I, and SAM-tosylate
have various sized anionic salts that potentially can affect the activity of AHL-synthases.
One objective of this work is to study how different formulations affect SAM substrate
activity with AHL-synthase.

Acyl-Acyl Carrier Protein (Acyl-ACP)
One reason AHL-synthases are difficult to study kinetically is because acyl-ACPs
are not commercially available. These substrates are synthesized within the bacterial cell
during type 2 fatty acid biosynthesis. There are two laboratory methods for preparing
acyl-ACPs; a chemical and enzymatic method.35
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In the chemical method for synthesizing BmaI1’s substrate octanoyl-ACP, an
activated octanoic acid is coupled with holo-ACP to make octanoyl-ACP. Cronan has
shown that fatty acid acyl-ACP’s can be prepared by chemical coupling of N-acyl
imidazole (an activated carboxylic acid) with holo-ACP in nearly quantitative yields
(Fig. 5).35
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Chemical synthesis of acyl-ACPs. An acylated carboxylic acid is
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carbonyl from the activated acid can be attacked by the nucleophilic thiol in holo-ACP.
In the enzymatic method, the enzyme Sfp from Bacillus subtilis (a
phosphopantetheinyl transferase) converts acyl-CoA to acyl-ACP (Fig. 6).35 The
pantethiene linker and acyl chain in the acyl-ACP is provided from the acyl-CoA. The
broad substrate specificity of Sfp enzyme is especially convenient in making several acylACPs from their corresponding acyl-CoAs using this method.
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Enzymatic preparation of acyl-ACP. Acyl-CoA couples with apo-ACP
by nucleophilic attack of the serine hydroxyl of apo-ACP on the phosphate bond shown.
The phosphopantethein transferase, Sfp, is the enzyme that aids this conversion.
Several methods have been reported in the literature for purifying apo-ACP and
acyl-ACPs. Among them, research groups have routinely precipitated and resuspended
the protein. Literature suggests that the purification of apo-ACP from E. coli DK547 is
optimal when precipitating the lysate with trichloroacetic acid and sodium deoxycholate,
and that acyl-ACP can be successfully purified by precipitation in acetone and resuspendion in a Tris-HCl buffer.13,36,37 However, to the best of our knowledge, there has
been no systematic study on how precipitation and resuspension affects ACP activity.
When performing enzymatic studies using acyl-ACP substrates, it is necessary to obtain
the native and therefore most active substrate. An objective of this work is to determine
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how precipitation and resuspendion of apo-ACP and acyl-ACP affects AHL-synthase
activity.

AHL-synthase Assay: DCPIP Assay
Tipton and coworkers reported a colorimetric assay that measured the activity of
the AHL-synthase RhlI.13 This colorimetric assay utilized UV-Vis spectroscopy and the
chemical known as 2,6-dichlorophenolindophenol (DCPIP). DCPIP is an oxidizing agent
that absorbs at 600 nm. Specifically, DCPIP reduces free thiols. One product of all
AHL-synthase reactions is holo-ACP. Holo-ACP contains a free thiol that can be
oxidized by DCPIP (Fig. 7). There are two reduction sites for DCPIP, so for every 2
molecules of holo-ACP produced, one molecule of DCPIP is reduced. The concentration
of thiol released as a function of time can be measured by following the dye reduction
reaction at 600 nm. This method was optimized at pH 7.2 in MES buffer for BmaI1 and
was utilized when measuring kinetic constants.
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Proposed mechanism for BmaI1 with DCPIP. DCPIP absorbs at 600
nm. Two molecules of holo-ACP reduce one molecule of DCPIP. The concentration of
holo-ACP released can be measured as a function of time. This work studied alternative
substrates along with native substrates for BmaI1 using this assay.
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AHL-synthase Structure Studies
As mentioned previously, the crystallization of a AHL-synthase bound to
substrate have not been successful. Therefore, information concerning substrate active
site binding is limited. However, two apo AHL-synthase ribbon structures, EsaI and
LasI, have suggested conserved regions of substrate binding sites for all AHL-synthases
(Fig. 8).38-40 The ribbon structures for these enzymes share similarities in binding sites
for the acyl chain in acyl-ACP, the ACP, and SAM. The overall structure for these
enzymes is a three-layer alpha-beta-alpha sandwich consisting of 8 helices and 9 twisted
beta-sheets. These structures closely resemble the acyl-CoA-N-acyl-transferase fold
family of proteins.38
The ACP binding site was hypothesized from mutagenesis, reporter assays, and
structural comparison studies. Acyl carrier protein (apo-ACP) is a 9 kD protein used in
fatty acid biosynthesis as a way of transferring hydrophobic fatty acid chains to
enzymatic domains so to synthesize phospholipids and other specialized products,
including lipid A, lipoic acid, and AHLs. 41-43 Apo-ACP has a conserved four-helix
bundle. The fatty acid chain covalently attaches to the phosphopantetheine prosthetic
group at the N-terminal end of the helix II in apo-ACP and is located within the
hydrophobic interior of this bundle. Computational, crystallographic, and mutagenic
studies implicate the acidic central helix II as a “recognition helix” for interaction with
most of the ACP enzyme partners.44 Enzyme-ACP interactions are predominantly
electrostatic. Since the recognition helix (helix II) in ACP is negatively charged, a region
of the AHL-synthase should have overall positive charge to electrostatically interact. In
fact, there are basic residues along alpha-7 and beta-8 in AHL-synthases that form a
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positively charged patch on the surface (see Fig. 8 for description of amino acids
involved in ACP binding). The flexible loop in LasI and an additional helix close to SAM
binding site in EsaI also aid in ACP binding to the enzyme. Both of these regions are
suggested to be involved in binding of the holo-ACP portion of acyl-ACP substrate in
this enzyme.

Figure 8.
Ribbon Structures for AHL-synthase. (A) LasI AHL-synthase
indicating substrate binding sites. ACP binding site for LasI involve residues including
Lys150, Arg154, Arg161, His165, Lys167, and Arg172. Acyl-chain binding pocket
resides in the V-cleft and contains the residues Trp33, Trp69, Met79, leu102, Leu122,
Met125, Leu140, Thr142, Thre144, Val148, Met151, Met152, Ala155, Leu157, Ile178,
and Leu188; specific for LasI. (B) EsaI AHL synthase ribbon structure with 3-oxohexanoyl-ACP bound in V-cleft. 38-40
The acyl chain binding site in AHL-synthase is a V-shaped deep cleft (beta-4 and
beta-5 in LasI structure shown) comprised of mostly hydrophobic residues (see Fig. 8 for
description of hydrophobic residues in LasI). This hydrophobic domain accommodates
the acyl side chain in the active site.38-40 For LasI, the V-cleft extends deeply because the
natural substrate, 3-oxo-dodecanoyl-HSL, has a long acyl-chain. The acyl-ACP in EsaI
is 3-oxo-hexanoyl-ACP. In this enzyme, the V-cleft is filled with hydrophobic residues
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that narrow the depth to fit the shorter acyl-chain. From these two ribbon structures, it is
hypothesized that the V-cleft is modulated according to the acyl-ACP chain length.
An important question to consider is whether alternative acyl-ACPs fit in the Vcleft and turn over. Ideally, the V-cleft for LasI could fit acyl chains varying from twelve
to two carbons in position. Likewise, the V-cleft of EsaI could fit acyl chain lengths
varying from six to two carbons. Interestingly, it has also been shown that RhlI can make
hexanoyl-HSL (C6HSL), which is two carbons longer than the native butyryl-HSL
(C4HSL). This indicates that the V-cleft in the active site can accommodate different
substrates. The native acyl-ACP for BmaI1 is C8ACP. The work described in this thesis
explores whether the V-cleft in BmaI1 can turn over shorter or longer acyl chains. I
hypothesize that studying alternative substrates with BmaI1 can provide clues into AHLsynthase’s selectivity for the native substrate.

AHL Signal Specificity in Gram-negative Bacteria
Bacterial acyl-ACPs are synthesized in vivo via type II fatty acid biosynthesis
(Fig. 9). This process begins when acetyl-CoA is converted to malonyl-CoA by the
enzyme acetyl-CoA carboxylase (ACC). Then, malonoyl-CoA couples with malonylCoA:ACP transferase (FabD) to produce malonyl-ACP. Malonyl-ACP combines with
acyl-ACP using 3-ketoacyl-ACP synthase (FabB). This produces 3-ketoacyl-ACP. From
here, a series of reductions, oxidations, and eperimizations produces the elongated acylACP. Further elongation can continue as the acyl-ACP combines with more malonylACP. These acyl-ACPs can be made into phospholipids, lipid A, lipoic acid, and AHLs.
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Figure 9.
Type II fatty acid biosynthesis. Continued elongation cycles produce a
large cellular pool of acyl-ACPs.
AHL-synthase specificity ensures the correct AHL signal is produced. During
type II fatty acid biosynthesis, there are multiple acyl-ACPs in the cytosol. Hoang et al.
have shown that if β-ketoacyl ACP reductase (FabG) in fatty acid biosynthesis pathway
is rate limiting, LasI synthesized increased amounts of short chain 3-oxo-AHLs both in
vitro and in vivo.43 This suggests that AHL-synthases can make nonspecific AHL if
conditions are limiting.45 However, mass spectrometry and HPLC studies of AHLsynthases reveal one predominate AHL in each bacterial species.45 This means that AHLsynthase must react with one acyl-ACP substrate to produce one AHL signal. If the right
acyl-ACP were not chosen, then AHL-synthases would make multiple AHLs and some of
them could be inhibitory to QS. This would result in increased noise in bacterial
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signaling that waste cellular energy resources and lead to an inefficient signaling system
in bacteria.
The mechanism of tight signal specificity in generation of QS signal is an
unsolved mystery. One possible scenario is that fatty acid biosynthesis is regulated to
selectively produce the desired acyl-ACP substrate. However, since fatty acid
biosynthesis is interconnected to multiple metabolic pathways, it is unlikely to serve as
major regulatory point to control QS signal selectivity. An alternative scenario is that
AHL-synthase enzymes effectively discriminate between native and nonspecific acylACP substrates. If this is true, AHL-synthase enzymes must be able to discriminate
between native acyl-ACP and nonspecific acyl-ACP substrates at one or more of the
following steps: viz., binding, catalysis and/or product release (Fig. 10). If a nonspecific
substrate binds to AHL-synthase, the enzyme should somehow keep reaction rates with
such substrates low enough so that nonspecific signals do not accumulate in the
environment. How the enzyme distinguishes between native and nonspecific acyl-ACP
substrate is not well understood. Another key objective of this thesis is to understand how
BmaI1 recognizes its cognate C8ACP from shorter and longer chain noncognate acylACPs.
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AHL-synthase Kinetic Mechanism
AHL-synthase follows a bi-ter mechanism (2 substrates, 3 products). The order of
substrates addition and product release is referred to as the kinetic mechanism. Substrates
add to the enzyme through one of the three possibilities: a) the substrates sequentially add
in an obligatory order, b) the substrates add sequentially in a random fashion, or c) the
substrates add via ping-pong mechanism where the first product is released before the
second substrate adds to the enzyme (Fig. 11). The following rules are followed while
representing a kinetic mechanism. Enzyme forms are named beginning with ‘E’.
Substrates are named A (first substrate to bind), B (second substrate to bind), C (third
substrate to bind) while products are named P (first product released), Q (second product
released), R (third product released) etc. For the RhlI enzyme, substrates add in a
sequential manner with SAM substrate binding first to the enzyme and MTA being the
last product to be released from the enzyme active site.13,41,46 However, it is not clear
whether all AHL-synthase enzymes follow this mechanism and so it is important to
determine the order of substrate binding and product release for the BmaI1 enzyme.
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Figure 11.
Kinetic mechanism for bi-substrate enzyme mechanism. (A) Substrates
sequentially add in an obligatory order, (B) Substrates add sequentially in a random
fashion, (C) Substrates add via ping-pong mechanism where the first product is released
before the second substrate adds to the enzyme.
Initial rates for bi-substrate enzymes displaying sequential mechanism (both
ordered and random) as a function of substrate concentration is given by the Cleland
equation below:

𝑉0 =
Here

𝑉max 𝑎𝑏
𝐴
𝐵
𝐵 𝑎 + 𝐾𝐴 𝑏
𝐾𝑖 𝐾𝑚 + 𝐾𝑚
𝑚

+ 𝑎𝑏

is the Michaelis constant for A at saturating concentrations of B
is the Michaelis constant for B at saturating concentrations of A

is the dissociation constant for EA complex.

Equation 1
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For the ping-pong mechanism, the

term in the denominator drops out in

Equation 1. Equation 2 is representative of the initial rate for a bi-substrate enzyme
displaying a ping-pong mechanism.

𝑉0 =

𝑉𝑚𝑎𝑥 𝑎𝑏
𝐵
𝐴 𝑏+𝑎𝑏
𝐾𝑚 𝑎+ 𝐾𝑚

Equation 2

These equations can be simplified into a simple Michaelis-Menten (data is interpreted
using Michaelis-Menten kinetics) form when one of the substrate’s concentrations is held
constant. For instance, if Equation 1 has substrate ‘b’ at a fixed concentration and
substrate ‘a’ at variable concentrations, then the equation reduces to the following
Michaelis-Menten form used to describe a single-substrate enzyme reaction:

𝑉0 =

𝑉𝑀𝑎𝑥 [𝑎]

Equation 3

𝐾𝑚 +[𝑎]

The double reciprocal of Equation 3 will adjust the equation to a linear form
(y = mx + b).
1

𝑉0

=

𝐾𝑚
𝑉𝑚𝑎𝑥 [𝑎]

+

1

𝑉𝑚𝑎𝑥

Equation 4

Equation 4 determines the terms for slope and intercept for single substrate kinetics

𝑆𝑙𝑜𝑝𝑒 =

𝐾𝑚

𝑉𝑚𝑎𝑥

𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 =

1

𝑉𝑚𝑎𝑥

Experimental results are commonly represented in double reciprocal plots.
Generated from Equation 1, the double reciprocal plot for a bi-substrate enzyme will have
the linear form:
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A double reciprocal plot generated from Equation 2 will have the linear form:
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Equation 6

The slope and intercept for random and ordered sequential mechanism at fixed
concentration of ‘b’, using Equation 4 are described below.
𝐴
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Equation 7

Equation 8

The slope and intercept for a ping-pong mechanism at fixed concentration of ‘b’, using
Equation 6 are described below.
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In the work described herein, BmaI1 was assayed using fixed concentration of
one of the substrate while varying the other. The effect of change in concentration of
fixed substrate on the slope and intercept of a double reciprocal plot revealed if the
BmaI1 mechanism for acyl-ACP and SAM substrates is ping-pong or random/sequential.
The patterns of the lines from the experimental data predicted bisubstrate kinetic
mechanisms. Parallel line patterns are usually indicative of a ping-pong mechanism.
Since Equation 2 for ping-pong mechanisms does not have the

term, the equation
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for slope becomes independent of fixed substrate concentration, ‘b’. Therefore, the slope
is unaffected upon change in ‘b’ and a parallel line pattern results (Equation 9).
Intersecting lines (Fig. 12) indicate a sequential/random mechanism (Equation 7 and 8).
It is important to note, however, that if the KiA is small compared to the KmA, then
parallel lines will result for a sequential and random mechanism.

Figure 12.
Line-Weaver Burk Plots. Enzyme assays are performed using fixed
concentration of one of the substrates (B in this figure), while varying the other. Each
line in this plot corresponds to a specific concentration of B. As B varied between
experiments, either the slope or intercept or both will change depending on the
mechanism of addition of two substrates. Parallel lines do not have slope effects,
whereas intersecting lines show a slope effect. If lines intersect at a point other than the
Y-axis, then an intercept effect results.
Thesis Objectives
The primary objectives in this thesis are to address the following questions:
a) Does precipitation and re-suspension affect acyl-ACP activity with BmaI1 AHLsynthase?
b) Does BmaI1 activity change with different SAM formulations, such as SAM-chloride
and SAM-tosylate?
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c) How does acyl-ACP substrate activity change with acyl chain length? How does the
catalytic efficiency of a shorter or longer chain acyl-ACP substrate compare with native
substrate?
d) Does the kinetic mechanism for BmaI1 change between specific and nonspecific
substrates? If this is true, can we get additional insight on how this enzyme discriminates
between specific and nonspecific acyl-ACP substrate?
This is the first study to report differences in rates and mechanism for nonspecific acylACP substrate reacting with an AHL-synthase. The BmaI1 substrate specificity study
described in this thesis is the first step towards solving the mystery of how AHL-synthase
enzymes achieve tight signal specificity in bacterial QS.
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CHAPTER TWO: MATERIAL AND METHODS

Materials and Equipment
All chemicals used for these projects were purchased from Sigma Aldrich. All
acyl-ACPs were purchased from Life Science Resource Corp. PD10 columns were
purchased from GE Life Sciences. All UV-Vis spectrophotometric data was obtained
using a Thermo Scientific Evolution 260 Bio UV-Vis spectrophotometer. All samples
were analyzed in Fisher 1 cm path length quartz cuvettes (14-385-928C). HPLC data
was obtained using a Thermo Scientific Accela HPLC system along with a Thermo
Scientific Hypersil Gold C18 reverse-phase UHPLC column (25002-054630).
Transformation occurred using a BTX ECM 630 electroporator from Dr. Cornell’s lab at
Boise State University.

Transformation of BmaI1 Plasmid
A vial containing E. coli Turner DE3 competent cells (~20 µL) was placed on ice
along with the BmaI1 plasmid was obtained from Professor Greenberg’s laboratory at the
University of Washington. Electro-cuvettes were cooled for a minimum of 10 minutes at
-20 °C. Once the competent cells were thawed (in a sterile environment), the plasmid
(1 µL) was added to these cells. The ligation/plasmid mixture was transferred to the
cooled electro-cuvettes and inserted into the electroporator. A pulse was applied for
transformation to occur (standard conditions were applied to the electroporator for
transformation). Immediately after the pulse, sterile LB broth (20 µL) was added to the
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cuvette and this solution was transferred to an Eppendorf tube. This was placed in a
shaker for one hour at 37 °C, 225 RPM for growth. The turbid solution was partitioned
and plated onto agar plates with streptomycin antibiotic selection (100 µg/mL).

BmaI1 Growth, Expression, and Purification
Two liters of Luria Bertani broth with 100 µg/mL streptomycin were inoculated
with BmaI and grown at 37 °C to an OD600 of 0.5-0.6. Expression was then induced by
addition of 0.5 mM IPTG. Growth cultures were then cooled to 16 °C and allowed to
express and grow overnight. Growth cultures were then centrifuged at 4,500 x g at 4 °C
for 15 minutes to pellet cells and stored at -20 °C prior to lysis. Cell pellets were thawed
on ice for 45 minutes prior to lysis. The cell pellet was suspended in 2 mL of B-PER
reagent was added per liter of growth to re-suspend pellet. 20 µL of (1 mg/mL) DNase
and RNase and 25 µL of (13 mg/750 µL IPA) phenylmethylsulfonyl fluoride (PMSF)
were added per liter of culture. Lysate was incubated at room temperature for 15 minutes
under gentle shaking before centrifugation at 13,000 x g for 10 minutes. Supernatant was
collected and stored on ice prior to purification. Purification was done via Ni2+ NTA
affinity chromatography. Ni2+ NTA column was equilibrated using 0.5M NaCl in 50 mM
Tris/HCl, pH 7.5 (Buffer A). Supernatant was loaded onto the Ni2+ NTA column and
washed with 10 mL of 50 mM imidazole in Buffer A. BmaI1 was eluted from the column
using 10 mL of 300 mM imidazole in Buffer A. Presence and purity of BmaI1 was
confirmed via SDS-PAGE analysis. Concentration was determined using UV-Vis (ε280 =
29450 M-1cm-1).
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Preparation of Precipitated ACP
Transformation of the ACP DK574 with pJT94 into BL21 E. coli competent cells
was peformed using the same conditions as the BmaI1 transformation discussed above.
Strain DK574 with pJT94 was grown in LB broth media with 15 μg/mL
kanamycin, 50 μg/mL streptomycin, 50 µg/mL spectinomycin, and 10 μg/mL
chloramphenicol. Acyl carrier protein and AcpH are induced by the addition of 100 μM
IPTG and incubation for another 3 to 4 hours. Cells were collected by centrifugation,
which were frozen for storage at -80 °C. The cell pellets were suspended in 2 mL B-PER
per liter of culture, 40 µL lysozyme per 1 liter of culture, 20 µL DNAse per liter of
culture, and 60 µL PMSF per liter of culture. This was kept at room temperature for 1520 minutes to lyse the cells. The lysate was cleared by centrifugation at ~13,000 x g for
30 minutes. MgCl2 was added to 25 mM and MnSO4 was added to 1.2 mM final
concentration. The cleared lysate was incubated at 37 °C for 4 hours to convert all acylcarrier protein to the apo-ACP form. Cellular protein was precipitated by the slow
addition of isopropanol to 50% with mixing and was incubated on ice for 1 hour. The
precipitated protein was removed by centrifugation at 10000 x g for 20 minutes. The
supernatant was stirred with 6 mL of de-fined Whatman DE52 diaminoethyl cellulose per
liter of culture overnight (ON). The media was packed into a column and washed with 10
column volumes of 10 mM lithium 4-morpholineethanesulfonate (MES) pH 6.1, 0.25 M
LiCl and eluted with 10 column volumes of 10 mM lithium MES pH 6.1, 0.5 M LiCl.
Fractions containing pure protein indicated by SDS PAGE were pooled and precipitated
by addition of 0.02% sodium deoxycholate and 5% trichloroacetate and incubation for 30
minutes. The suspension was pelleted by centrifugation at 14000 x g for 30 min and apo-
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ACP was resuspended in 0.5 M Tris-HCl pH 8.0. The suspended protein was then
desalted using PD10 column, concentrated (ε280 = 1490 M-1cm-1) using a 3 kD molecular
weight cutoff (MCO) spin filter column, and stored at -80 °C.46

Preparation of Unprecipitated ACP
Strain DK574 with pJT94 was grown in LB broth media with 15 μg/mL

kanamycin, 50 μg/mL streptomycin, 50 μg/mL spectinomycin, and 10 μg/mL

chloramphenicol. Acyl carrier protein and AcpH are induced by addition of 100 μM
IPTG and incubation for another 3 to 4 hours. Cells were collected by centrifugation,
which were frozen for storage at -80 °C. The cell pellets were suspended in 2 mL B-PER
per liter of culture, 40 µL lysozyme per 1 liter growth, 20 µL DNAse per liter growth,
and 60 µL PMSF per liter of culture. This was kept at RT for 15-20 minutes to lyse the
cells. The lysate was cleared by centrifugation at ~13,000 x g for 30 minutes. MgCl2 was
added to 25 mM and MnSO4 was added to 1.2 mM final concentration. The cleared
lysate was incubated at 37 oC for 4 hours to convert all acyl carrier protein to the apoACP form. Cellular protein was precipitated by the slow addition of isopropanol to 50%
with mixing and was incubated on ice for 1 hour. The precipitated protein was removed
by centrifugation at 10000 x g for 20 minutes. The supernatant was stirred with 6 mL of
de-fined Whatman DE52 diaminoethyl cellulose per liter growth ON. The media was
packed into a column and washed with 10 column volumes of 10 mM lithium 4morpholineethanesulfonate (MES) pH 6.1, 0.25 M LiCl and eluted with 10 column
volumes of 10 mM lithium MES pH 6.1, 0.5 M LiCl. Fractions containing pure protein
indicated by SDS PAGE were pooled and desalted using PD10 column. This was then
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concentrated (ε280 = 1490 M-1cm-1) using a 3 kD MCO spin filter column and stored at
stored at -80 °C.

Preparation of Unprecipitated acyl-ACP
Phosphopanetheinyl transferase, Sfp from Bacillus subtilis, was used to modify
apo-ACP with acyl-CoAs to yield acyl-ACPs. The 2 mL transferase reaction contained
50 mM Tris-HCl pH 6.8, 10 mM magnesium chloride, 750 µM apo-ACP, 937 µM acylCoA (1.25X apo-ACP), and 3 µM Sfp. Acyl-CoAs were added last. For acyl-CoAs with
carbon chain lengths greater than eight, precipitation occurs and stops the reaction from
going to completion. Therefore, the volume of C10-CoA was partitioned and added to
the solution over 15 minute intervals. This reaction was incubated at 37 °C and
monitored by UHPLC for completion. The reaction time varied from 15 minutes to 2.5
hours. Then, ammonium sulfate at 75% saturation was added to the solution for 1 h at 4
°C and Sfp was precipitated and collected by centrifugation (13,000 x g for 15 minutes).
The clear acyl-ACP solution was desalted by multiple washes using a 3kD MCO spin
filter column. The desalted acyl-ACP was concentrated using a 3kD MCO spin filter
column and stored at -80°C.

Preparation of Precipitated acyl-ACP
Phosphopanetheinyl transferase, Sfp from Bacillus subtilis, was used to modify
apo-ACP with acyl-CoAs to yield acyl-ACPs. The 2 ml transferase reaction contained 50
mM Tris-HCl pH 6.8, 10 mM magnesium chloride, 750 µM apo-ACP, 937 µM acyl-CoA
(1.25X apo-ACP), and 3 µM Sfp. Acyl-CoAs were added last. For acyl-CoAs with
carbon chain lengths greater than eight like decanoyl-CoA (C10CoA) precipitation occurs
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and stops the reaction from going to completion. Therefore, the volume of these acylCoAs were partitioned and added to the solution over 15 minute intervals. These
reactions were incubated at 37 °C and monitored by UHPLC for completion. The
reaction time varied from 15 minutes to 2.5 hours. Then, ammonium sulfate at 75%
saturation was added to the solution for 1 h at 4 °C and Sfp was precipitated and collected
by centrifugation (13,000 x g for 15 minutes). Acyl-ACP was precipitated with two
volumes of acetone overnight at -20 °C. The precipitate was collected by centrifugation
and briefly dried. Precipitated acyl-ACP was re-suspended in 15 mL of 25 mM Tris-HCl
pH 7.5 and desalted by washing multiple times using a 3kD MCO spin filter column. The
desalted acyl-ACP was concentrated using a 3kD MCO spin filter column and stored at
-80 °C.

Acyl-ACP Separation Using UHPLC
Using a UHPLC analytical C18 column, acyl-ACP purification was determined.
Solvent A consisted of H2O + 0.1% TFA and solvent B consisted of acetonitrile (ACN) +
0.1% TFA. At flow rate of 600 µL/min, a gradient of 75% A and 25% B was initiated and
over a ten minute period changed to 25% A and 75% B.

Electrospray Ionization Mass Spectrometry
Molecular mass of ACP and its derivatives were determined using a Bruker maxis
Quadrupole-Time-of-Flight (Q-TOF) mass spectrometer equipped with an Electrospray
Ionization (ESI). Ten microliter of samples were injected onto a Phenomenex C18
column (100 x 2.1 mm, 2.6µ) followed by a simple linear gradient for sample desalting
and separation. The initial eluent was 98% mobile phase A (99.9% water, 0.1% formic
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acid) and 2% B (99.9% acetonitrile, 0.1% formic acid) for 5 min and then mobile phase B
was increased to 50% in 25 min. LC eluent was diverted to the waste during the first five
minutes of the gradient to eliminate salts in the sample buffer. Mass analysis was
performed using positive ion mode with a spray voltage of 4000V. Obtained mass spectra
were deconvoluted using Bruker Data Analysis 4.0 software tool to obtain charge state
(N) of protein ions. To calculate the molecular mass of ACP and its derivatives, the
measured m/z values were multiplied by corresponding N and were subtracted by the
mass of N protons (N x 1.0079). ACP: calculated average mass - 8508.3 Da, observed
mass - 8507.5 Da; C4ACP: calculated mass – 8916.8 Da, observed mass – 8918.2 Da;
C6ACP: calculated mass – 8944.9 Da, observed mass – 8946.2 Da; C8ACP: calculated
mass – 8973.0 Da, observed mass – 8974.4 Da; C10ACP: calculated mass – 9000.8 Da,
observed mass – 9002.3.

HPLC Method Addressing Ping-Pong Mechanistic Possibility
The experiments were conducted with using two methods. Method 1 separates
apo-ACP from acyl-ACPs and indicates the RT for BmaI1. Method 1 monitors the
appearance of holo-ACP and is ten minutes. Method 2 separates SAM from MTA and is
a sixty minute method that monitored the appearance of MTA. Solvent A is NanoPure
water + 0.1% TFA and solvent D is ACN + 0.1% TFA.
Method 1 used a 600 µL/min flow rate and started with 75% A and 25% B. Over
a ten minute period the gradient changed to 25% A and 75% B. For the C8ACP/BmaI1
test, a 1:1 mixture of C8ACP and BmaI1 enzyme were mixed at 40 µM in 100 mM
HEPES buffer pH 7.2. This mixture was then allowed to incubate at 37°C for 30 minutes
and then an additional 30 minutes with two HPLC injects occurring at T30 and T60.
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After 60 minutes, 10 µL of 12 mM SAM-Cl (sigma) was added to the reaction mixture
and allowed to incubate for 10 minutes before being injected onto the HPLC.
Method 2 used a 500 µL/min flow rate and started with 100% A and 0% D. Over
a ten minute period the gradient changed to 70% A and 30% D. For the SAM-Cl
(Sigma)/BmaI1 test, a mixture of SAM-Cl (Sigma) and BmaI1 were mixed at
concentrations of 100 µM and 45 µM respectively. A control was also made with only
100 µM SAM-Cl. The reaction and control were monitored for one hour. After no change
between the BmaI1 containing mixture and the control, 60 µM of C8ACP was then added
to the reaction mixture and a reaction was seen.

DCPIP Assay for BmaI1
The enzymatic reaction catalyzed by BmaI was monitored using a colorimetric
assay that is sensitive to the free thiol generated upon transfer of the acyl group from
either C8ACP or various acyl-ACPs. A typical reaction contained 30 uM DCPIP and 100
mM HEPES, pH 7.2. For C8ACP determination of Km and kcat, SAM was fixed at 3 mM
while C8ACP varied from 2-100 µM. For determination of Km and kcat for SAM, C8ACP was fixed at 25-30 µM. For generating curves with different acyl-ACP varying,
SAM was fixed at 3 or 6 mM while the acyl-ACP concentrations varied from 2-100 µM.
For generating curves with SAM varying, acyl-ACP was kept at 5-10X the acyl-ACP’s
Km. SAM, acyl-ACP, buffer, and DCPIP was incubated for 25 minutes before initiating
with enzyme to eliminate background rates. Reactions were initiated by the addition of
BmaI1 (200 nM for C8ACP, 560 nM C6ACP, 960 µM C10ACP and 2.86 µM C4ACP,
and 5 µM C8CoA). The thiol-dependent reduction of DCPIP was monitored at 600 nm
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(ε = 21000 M-1cm-1) for no more than 800 seconds. The initial rate data was fit to
Michaelis-Menten (Equation 3) or substrate inhibition equation using GraphPad Prism
6.0. All experiments were done in triplicate to check for reproducibility and to estimate
errors.
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CHAPTER THREE: RESULTS AND DISCUSSION

Enzyme Purification

BmaI1
The appearance of small white circular colonies on the streptomycin antibiotic selected
(100 µg/mL) agar plates confirmed that the transformation of BmaI1 into E. coli Turner
DE3 cells using electroporation was successful. Colonies were used to inoculate large
volumes of medium with streptomycin antibiotic selection (100 µg/mL). The large
culture reached OD600 = 0.5-0.8 within three hours of inoculating. Chemical lysing using
B-PER, DNase, RNase, and PMSF was fast and efficient in producing clear yellow lysate
(compared to sonication). The BmaI1 plasmid that was provided by Dr. Peter
Greenberg’s lab contained a 6-His tag for Ni-NTA affinity chromatography purification.
The molecular weight (MW) of BmaI1 using this sequence is 22938.1Da (Fig. 13A). It is
expected that fractions containing BmaI1 would show banding at ~23 kD. Analysis of
SDS-PAGE confirmed BmaI1 was isolated from Ni-NTA chromatography at ~23 kD
(Fig. 14).
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Figure 13.
Amino Acid Sequences for BmaI1 (A) and apo-ACP (B). Using
Protparam the MW for BmaI1 and apo-ACP was calculated to be 22115.2 Da and 8639.5
Da, respectively. Adjusting for the 6-His tag added to this sequence the MW is predicted
to be 22938.1 Da.
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Figure 14.
SDS-PAGE of BmaI1 2L culture using Ni-NTA chromatography:
Lane 1 (L1): EZ prestained protein ladder; Lane 2 (L2): Crude BmaI1; Lane 3 (L3):
BmaI1 Load; Lane 4 (L4): 50 mM imidazole in Tris-HCl buffer wash of BmaI1; Lane 510 (L5-L10): 200 mM imidazole in Tris-HCl buffer Elutions 1-6. BmaI1: MW - 22938.1
Da. The 25 kD marker is the third line up from the bottom and the elutions in lanes 5-10
are slightly below the 25 kD marker. These bands are around 23 kD and were
concentrated to 1.5 mL at 97 µM.
Apo-ACP (Precipitated and Unprecipitated)
The appearance of small white circular colonies on agar plates with the
kanamycin (15 μg/mL), streptomycin (50 μg/mL), spectinomycin (50 μg/mL), and
chloramphenicol (10 μg/mL) antibiotic selection confirmed the transformation of apoACP into BL21 E. coli competent cells using electroporation was successful. Colonies
were used to inoculate large growths with the same antibiotic selection as the plates. The
culture reached OD600 = 0.5-0.8 within four hours of inoculating. Chemical lysing using
B-PER, DNase, RNase, lysozyme, and PMSF was fast and efficient in producing clear
yellow lysate (compared to sonication). All cells produce holo-ACP during fatty acid
biosynthesis and thus when isolating apo-ACP there is always holo-ACP contamination.
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Since these two proteins are similar in structure and molecular weight, separating one
from the other is a laborious process. Therefore, Dr. Peter Greenberg’s lab included an
additional gene, ACPH (ACP-hydrolase), in the plasmid that converted holo-ACP to apoACP by the addition of MgCl2 and MnSO4 to the clear lysate. The conversion of holoACP to apo-ACP produces a cloudy lysate. ACP hydrolase was precipitated with IPA
and gave a white solid. Removal of ACP hydrolase with centrifugation yielded a clear
lysate. Anion exchange chromatography was used to successfully isolate pure fractions
of apo-ACP from other cellular debris. The amino acid sequence of apo-ACP is shown
in Fig. 13B and this sequence has a MW of 8639.5 Da. It is expected that fractions
containing apo-ACP would show banding at ~9 kD. Analysis of SDS-PAGE confirmed
that apo-ACP was isolated by anion exchange chromatography at ~9 kD (Fig. 15).

Figure 15.
SDS-PAGE of apo-ACP 2L culture using anion exchange
chromatography: Lane 1 (L1): EZ prestained low range protein ladder; Lane 2 (L2):
Column wash with 10 mM MES + 0.5 mM LiCl pH 6.13; Lanes 3-10 (L3-L10) contains
elutions 1-8 using10 mM MES + 0.5M LiCl pH 6.13. Apo-ACP: MW - 8639.5 Da.
Apo-ACP is isolated in lanes 4-10 and were concentrated to 1.5 mL at 12 mM.
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Substrate Synthesis

Acyl-ACP Purification
The syntheses of all acyl-ACPs were confirmed by HPLC (Fig. 16). Apo-ACP
elutes at 6.0 minutes using the Method 1 described previously. The addition of the acylpantetheine linker (Fig. 17) and acyl chain to apo-ACP shifts the retention time (RT) for
each substrate accordingly.

Figure 16.
HPLC chromatograms of apo-ACP and acyl-ACPs using Method 1.
(A) Apo-ACP eluted at 6.0 minutes; disappearance of this peak was monitored over time
to confirm successful synthesis of acyl-ACPs. Contamination of holo-ACP was
monitored by the appearance of a peak at 5.2 minutes. All samples shown are free of
holo-ACP. (B) Butyryl-ACP (C4ACP) eluted at 5.5 minutes and was completed within
15 minutes. (C) Hexanoyl-ACP (C6ACP) eluted at 5.8 minutes and was completed
within 15 minutes. (D) Octanoyl-ACP (C8ACP) eluted at 6.2 minutes and was
completed within 30 minutes. (E) Decanoyl-ACP (C10ACP) eluted at 6.6 minutes and
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had C10CoA partitioned over a two-hour period. After addition of all C10CoA, the
reaction was complete within 30 minutes.
Enzymatic synthesis of acyl-ACPs requires the acyl-CoA stock to be pure. If the
stock has free acid CoA, then holo-ACP will contaminate the reaction (Fig. 17). HoloACP is a product of AHL-synthase BmaI1 enzymatic reactions and can inhibit
experimental rates.
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Figure 17.
Enzymatic synthesis of holo-ACP from free acid CoA, apo-ACP, and
Sfp. Free acid CoA reacts freely with apo-ACP and is converted to holo-ACP with Sfp.
Holo-ACP is a product of AHL-synthase BmaI1 enzymatic reactions and can inhibit
experimental rates. The portion outlined in blue is the pantetheine linker that
differentiates holo-ACP from apo-ACP.
To successfully study this enzyme with acyl-ACP substrates, there cannot be
holo-ACP present. Using the Method 1, holo-ACP elutes at 5.2 minutes. Each acyl-ACP
used is free of holo-ACP and has distinct RTs from apo-ACP. These reactions are
monitored by the depletion of the apo-ACP peak and the growth of the corresponding
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acyl-ACP peak. The enzyme used for this reaction is Sfp and it elutes at 3.1 minutes. It is
important to keep track of the final volume of the completed reaction because this volume
is needed to assess the amount of ammonium sulfate needed to precipitate out Sfp. Once
the enzyme has been removed from the reaction, multiple washes to remove excess acylCoA and ammonium sulfate are needed to synthesize a clean acyl-ACP substrate. These
molecules absorb UV-Vis light at 260 nm whereas apo-ACP absorbs this light at 280 nm.
Therefore, monitoring the reduction of the 260 nm peak during each wash determined
when each acyl-ACP was free of contamination.

Acyl-ACP Characterization
The syntheses of all acyl-ACPs were successfully confirmed by MS (Fig. 18).
The obtained mass spectra were deconvoluted using the Bruker Data Analysis 4.0
software tool to obtain the charge state (N) of protein ions. To calculate the molecular
mass of ACP and its derivatives, the measured m/z values were multiplied by
corresponding N and were subtracted by the mass of N protons (N x 1.0079). ACP can
exist in two forms where a methionine residue is oxidized and where it has been
truncated. Both of these forms were observed using this method. The calculated average
mass of ACP is 8508.3 Da and its observed mass using this method was 8507.5 Da;
C4ACP has a calculated mass of 8916.8 D and was observed at 8918.2 Da; C6ACP has a
calculated mass of 8944.9 Da and its mass was observed at 8946.2 Da; C8ACP has a
calculated mass of 8973.0 Da and its mass was observed at 8974.4 Da; C10ACP has a
calculated mass of 9000.8 Da and was observed mass at 9002.3 Da.
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Figure 18.
ESI Mass Spectra of ACP and its derivatives in positive ion modes.
ACP: calculated average mass - 8508.3 Da, observed mass - 8507.5 Da; C4ACP:
calculated mass – 8916.8 Da, observed mass – 8918.2 Da; C6ACP: calculated mass –
8944.9 Da, observed mass – 8946.2 Da; C8ACP: calculated mass – 8973.0 Da, observed
mass – 8974.4 Da; C10ACP: calculated mass – 9000.8 Da, observed mass – 9002.3 Da.
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Effect of ACP Precipitation on Substrate Activity
Prior studies have shown that ACP conformation changes while interacting with
different enzyme partners, but it has not been studied whether apo-ACP precipitation and
resuspension results in subtle conformational changes in structure. We have found that
the most active substrate with BmaI1 has had ACP precipitated with sodium
deoxycholate and trichloroacetic acid and acyl-ACP not precipitated with the addition of
acetone (Fig. 19).

Figure 19.
Effects of ACP precipitation on BmaI1 activity. (A) Velocity vs. [C8ACP]; ACP was precipitated with TCA and sodium deoxycholate and C8-ACP wasn’t
precipitated with acetone. This preparation of substrate is the most active. (B) Velocity
vs. [C8-ACP]; ACP is precipitated with TCA and sodium deoxycholate and C8-ACP was
precipitated with acetone. This is the second most active preparation of substrate. (C)
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Velocity vs. [C8-ACP]; ACP wasn’t precipitated and the C8-ACP wasn’t precipitated.
This was the least active preparation of substrate.
Table 2 shows the relative % of kcat/Km for each substrate. The kcat is a MichaelisMenten parameter that can be calculated as Vmax/[E] and its units are 1/seconds. It is
referred to as the ‘turn-over’ number and it is equivalent to the amount of substrate
converted to product in one second. kcat/Km is the specificity constant referred to as the
catalytic efficiency. This term explains how fast the enzyme reacts with the substrate
once it encounters the substrate. Usually, the upper limit of kcat/Km is determined by the
rate of diffusion because the substrate has to diffuse and collide with the enzyme and fit
into the active site before it can be converted to product. For BmaI1 DCPIP assays, the
catalytic efficiency is greatest for ACP precipitated and C8ACP unprecipitated.
Precipitating both samples causes a 3-fold decrease in efficiency and omitting the
precipitation step for proteins causes a 6-fold decrease in the efficiency.
Table 2. C8ACP preparation and determination of Km, kcat, kcat /Km, curve type,
and substrate inhibition
Variable
S

Fixed
S

kcat
(min-1)

Km
(µM)

kcat/ Km
(µM-1)(min-1)

#

kcat/ Km
Relative %

ACPP,
SAM100 %
5.8 ±
6±1
0.96 ± 0.18
C8ACPU
Cl
0.6
ACPP,
SAM35 %
3.7 ±
11 ± 3
0.34 ± 0.09
C8ACPP
Cl
(3-fold)
0.2
ACPU,
SAM16 %
4.6 ±
30 ± 6
0.15 ± 0.03
C8ACPU
Cl
(6-fold)
0.5
acyl-ACP
ACPP,C8ACPU
# kcat/ Km Relative % = [{kcat/ Km}
/{kcat/ Km}
]

Curve

Substrate
Inhibition

Hyperbolic

Yes

Hyperbolic

No

Hyperbolic

No

Effect of SAM Formulation on Substrate Activity
The commerically available formulations of SAM-Cl and SAM-tosylate were
assayed with BmaI1 and C8ACP. Commercially available formulations of SAM are
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known to break down into MTA and HSL, which have the potential to inhibit BmaI1
activity. Additionally, the anionic salts that stabalize SAM such as chloride and tosylate
can affect the activity of BmaI1. Tosylate is a bulky conjugated compound compared to
chloride (Fig. 20). The anionic salts could bind to BmaI1 and produce conformational
changes that could inhibit the enzyme’s ability to turn over C8ACP.

NH2
N

O
S

HO
NH2

Cl

O

N

NH2

N

N

O

N

S

HO
NH2

2HCl

O

N

O

N
2HCl

O

OH OH

N

OH OH

S
O

SAM-Cl

SAM-tosylate

Figure 20.
SAM-chloride and SAM-tosylate structures.
All commercially
available formulations of SAM are stored in acidic conditions. SAM-Cl has a small
anionic chloride while SAM-tosylate contains a larger MW salt that is conjugated.
When testing SAM-Cl and SAM-tosylate, Km and kcat values were not
differentiable in comparison (Fig. 21). SAM-Cl Km is 1.8 ± 0.3 mM and SAM-tosylate is
0.9 ± 0.2 mM. The kcat for SAM-Cl is 5.8 ± 0.8 min-1 and for SAM-tosylate it is 6.2 ± 0.4
min-1. BmaI1 activity doesn’t change with different SAM formulations such as SAMchloride and SAM-tosylate. This indicates that either substrates can be used with the
DCPIP assay to study BmaI1. This is advantageous for laboratories that are restricted to
purchasing formulations of SAM when studying AHL-synthases. Interestingly, SAMtosylate at concentrations greater than 3 mM indicated decreased rates. The IC50 of
tosylate was tested and indicated inhibition occurring at 1 mM.
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Figure 21.
Effects of SAM formulations on BmaI1 activity. Both assays were
initiated with 200 nM BmaI1. A. SAM-Cl was used as the variable substrate and C8ACP
unprecipitated was fixed at 20 µM. Km (SAM-chloride) is 1.8 ± 0.3 mM; kcat is 5.8 ±
0.8 min-1; kcat/Km is 3.2min-1mM. B. SAM-tosylate was used as the variable substrate
and C8ACP unprecipitated was fixed at 20 µM. Km (SAM-tosylate) is 0.9 ± 0.2 mM;
kcat is 6.2 ± 0.4 min-1; kcat /Km is 6.9 min-1mM. SAM-tosylate at concentrations
greater than 3 mM indicated decreased rates. The IC50 of tosylate was tested and
indicated inhibition occurring at 1 mM.
Exploring the Kinetic Mechanism of BmaI1

DCPIP assay of BmaI1, C8ACP, and SAM
Plotting the double reciprocal of variable concentration of C8ACP and fixed
concentrations of SAM-Cl displayed a series of parallel lines (Fig. 22). Parallel line
patterns are indicative of a ping-pong mechanism (Fig. 23).
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Figure 22.
Double Reciprocal Plot of BmaI1, C8ACP, and SAM using the DCPIP
Assay. These assays are accomplished using variable concentrations of C8ACP ranging
from 0-100 µM while fixing SAM. Five assays were completed using different
concentrations of SAM-Cl ranging from 250-1500 µM. The KiA of C8ACP is 125 ± 43
nM. Plotting the double reciprocal of the data generates a series of parallel lines. This
indicates the enzymatic mechanism is ping-pong.47
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Ping-Pong Mechanism for bi-substrate Kinetics

The double reciprocal Michaelis-Menten equation for a bisubstrate ping-pong
mechanism is
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Ping-pong mechanisms slope becomes independent of fixed substrate
concentration. In this case, SAM-Cl was fixed while varying C8ACP. At times, parallel
lines can result for sequential and random mechanisms. The double reciprocal MichaelisMenten equation for these mechanisms is
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Parallel lines for random and ordered sequential mechanisms occur when the KiA

is small compared to the KmA. This study obtained the KiA for C8ACP to be 125 ± 43 nM
and the KmA for C8ACP is 6 ± 1 µM. The KiA is much less than the KmA, which suggests
that further experimentation is needed before deciding the mechanism is ping-pong.

Eliminating Ping-Pong Mechanism
A bi-substrate ping-pong mechanism involves one substrate adding to the enzyme
and converting to product immediately (Fig. 23). Therefore, if BmaI1 follows this
mechanism, when incubating BmaI1 with C8ACP product release should be observed.
Since acylation is dependent on the acyl-ACP substrate, holo-ACP is the expected
product to be released when incubating with only C8ACP (Fig. 24A). Lactonization is
dependent on the substrate, SAM, and HSL and MTA are the expected products to be
released when incubating only with SAM-Cl (Fig. 24B).
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Figure 24.
Expected Products when C8ACP is incubated with BmaI1 without
SAM-Cl (A) and when SAM-Cl is incubated with BmaI1 without C8ACP (B). HoloACP can only be released when C8ACP is acylated in the active site of BmaI1. When
incubating with only SAM-Cl lactonization alone can produce HSL and MTA.
Incubating SAM, C8ACP, and BmaI1 and injecting a sample for HPLC analysis
showed C8ACP depletion and holo-ACP turned over (Fig. 25A). Studying SAM-Cl
turnover is more difficult because the commercially available SAM-Cl can break down
into MTA. This means that there is a starting amount of MTA existing before enzyme is
added. In order to observe the amount of MTA that has naturally broken down from
SAM-Cl, the enzyme Methylthioadenosine/S-adenosylhomocysteine (MTA/SAH)
nucleosidase (MTN) was added. MTN catalyzes the irreversible cleavage of the
glycosidic bond in both 5'-methylthioadenosine (MTA) and S-adenosylhomocysteine
(SAH) to adenine and the corresponding thioribose, 5'-methylthioribose and Sribosylhomocysteine, respectively. When injecting 100 µM SAM-Cl with 1.6 µM MTN
over 45 minutes, there was no significant peak area change observed. Therefore SAM
and adenine seem to be stable under the reaction conditions (Fig. 26A and Table 3 and 4).
When BmaI1 was added to this sample, there was no significant change in peak area for
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SAM or adenine (Fig.26B). Adding C8ACP to this reaction showed a decrease in adenine
peak (Fig. 26C). Table 3 and 4 is a compilation of the quantitative data and sample
definitions for these experiments (Fig. 26). When incubating C8ACP and SAM
independently with BmaI1, there was also was no change in the chromatogram,
indicating the expected product of the ping-pong mechanism wasn’t produced (Fig. 25B).
Therefore, the mechanism must be random or ordered sequential.
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Figure 25.
HPLC chromatogram using Method 1: (A) Chromatogram showing 40
µM C8ACP and 40 µM BmaI1 incubated at time 30 (Blue) and the same reaction + 1.2
mM SAM at time 90 (red). Near complete conversion of the C8ACP to holo-ACP is seen
indicating active enzyme. C8ACP elutes at 6.15 minutes, holo-ACP at 5.2 minutes, and
BmaI1 at 6.75 minutes. (B) Chromatogram showing 40 µM C8ACP and 40 µM BmaI1
incubated at time 30 (Blue) and time 60 (red). There is no decrease in the C8ACP peak
nor any holo-ACP. Method 1 used a 600 µL/min flow rate and started with 75% A and
25% B. Solvent A is NanoPure water + 0.1% TFA and solvent D is ACN + 0.1% TFA.47
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Figure 26.
HPLC Chromatograms using Method 2: (A) Chromatogram of Control
showing 100 µM SAM-Cl and 1.6 µM MTN at time 0 (blue) and time 45 (red). No
significant peak area change is seen. Therefore, SAM and adenine seem to be stable in
reaction. (B) Chromatogram of Control at time 45 (Blue) and 19. 4 µM of BmaI1 reaction
at T60 (Red). No significant change in peak area for SAM or adenine is seen. (C)
Chromatogram of control reaction at time 60 (Blue) and BmaI1 reaction + 60uM C8ACP
at time 80 (Red). A significant decrease in SAM area is seen along with a significant
increase in the adenine peak as expected. Method 2 used a 500 µL/min flow rate and
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started with 100% A and 0% D Solvent A is NanoPure water + 0.1% TFA and solvent D
is ACN + 0.1% TFA.47
Table 3. Ping-pong mechanism experiment quantitative analysis with arbitrary
peak areas47
Run

Compound
SAM-Cl
MTA
Adenine
SAH
SAM/Adenine

Table 4.

100 µM
SAM
18.0271
2.8326
0
0.3673
NA

100 µM
SAM+ 1.6
µM MTN
18.7008
0
3.23526
0
5.7803

Control
T0
18.4890
0
3.16584
0
5.8401

Control
T45
18.8234
0
3.3975
0
5.5403

BmaI1 Rxn
T60
18.4155
0
3.16434
0
5.81970

BmaI1 Rxn
+ 60 µM
C8ACP
11.7485
0
9.4819
0
1.2390

Ping-pong mechanism experiment sample definitions47

SAM:
MTN:
BmaI1:
HEPES Buffer:
C8-ACP

Control
100 µM
1.6 µM
0 µM
100 mM
0 µM

BmaI1 Reaction
100 µM
1.6 µM
19.4 µM
100 mM
0 µM

BmaI1 Rxn + C8-ACP
100 µM
1.6 µM
19.4 µM
100 mM
60 µM

Acyl-Chain Length Specificity
To determine if BmaI1 activity changes with acyl chain length, four substrates
(C4ACP, C6ACP, C10ACP, and C8CoA) with variable concentrations were assayed with
SAM-Cl fixed. Figure 27 is a compilation of the Velocity vs. [Substrate] curves
generated using this approach. The appropriate enzyme concentration was determined
first by varying BmaI1 with saturating concentrations of both substrates. Incubating
DCPIP, SAM, acyl-ACPs, and C8CoA for 25 minutes depleted background rates. The
Km and kcat terms were used to determine activity.
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Figure 27.
Substrate-velocity curves for nonspecific acyl-ACP substrates reacting
with BmaI1. Initial rate as a function of substrate concentration for 3 mM SAM chloride
(fixed) and (A) varying C4ACP in 2 µM BmaI1 (B) varying C6ACP in 0.56 µM BmaI1
(C) varying C10ACP in 1 µM BmaI1 and (D) varying C8CoA in 5 µM BmaI1. The rate
curves were sigmoidal for poor substrates (C4ACP, C8CoA) and hyperbolic for C6ACP
and C10ACP substrates. The dissociation constant for C6ACP substrate inhibition is 69 ±
14 µM. Deviation from Michaelis-Menten behavior for C4ACP and C8CoA are
indicative of kinetic cooperativity. Positive cooperativity (Hill slope > 1) was observed
for both of these substrates. Acyl-ACP substrates were enzymatically synthesized from
apo-ACP and acyl-CoA. While apo-ACP was precipitated, all acyl-ACP samples
(C4ACP, C6ACP, and C10ACP) were prepared by omitting the acetone precipitation step
in substrate purification. C6ACP and C10ACP substrate-velocity data was fit to substrate
inhibition equation and Michaelis-Menten equation, respectively, while C4ACP and
C8CoA rate data was fit to Hill equation.
To understand if structural changes in fixed acyl-ACP substrates affected SAM
activity, four nonspecific acyl-ACP substrates (C4ACP, C6ACP, C10ACP, and C8CoA)
were fixed and assayed with variable concentrations of SAM-Cl. Figure 28 is a
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compilation of Velocity vs. [Substrate] curves generated using this approach. The
appropriate enzyme concentration was determined first by varying BmaI1 with saturating
concentrations of both substrates. Incubating DCPIP, SAM, acyl-ACPs, and C8CoA for
25 minutes depleted background rates.

Figure 28.
Substrate-velocity curves for SAM. A-D) Rate curves for SAM when
the fixed substrate was 150 µM C4ACP, 38 µM C6ACP, 36 µM C10ACP, and 522 µM
C8CoA, respectively. The enzyme concentrations were varied from 0.5 to 5 µM
depending on the acyl-ACP substrate used in the experiment. Substrate-velocity data for
C6ACP was fit to Michaelis-Menten equation to determine Km and kcat. Substrates that
produced a nonhyperbolic kinetic response were fit to Hill equation to determine
Michaelis constant and catalytic constant.
Table 5 is a compilation of the kinetic parameters measured using these substrates
with DCPIP. For each variable acyl-ACP, the Km are not all comparable. The Km for
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variable concentrations of C8ACP with fixed SAM-Cl is 6 ± 1 μM. C6ACP is only two
carbons chains shorter than C8ACP and has the most similar Km. C10ACP is only two
carbon chains longer and C4ACP, which is four carbons chains shorter, have the most
drastically increased values of Km. The data suggests that substrates with different acylchain lengths from C8ACP have values of Km increased and are less active. The kcat
decreased for alternative substrates. The kcat of C8ACP is 5.8 ± 0.6 min-1. Similarly to
the data described above, C6ACP has the most similar turn over number compared to
C8ACP. C10ACP is only two carbon chains longer and C4ACP, which is four carbons
chains shorter, have the most drastically decreased values of kcat. This data suggests that
substrates with different acyl-chain lengths from C8ACP have values of kcat decreased
and are less active. Therefore, this data supports that variation in acyl-chain length for
acyl-ACPs decreases the activity of BmaI1.
The relative catalytic efficiency all acyl-ACPs and C8CoA were compared in
Table 5. C6ACP is only two carbons shorter than the natural substrate and the relative
kcat/Km is 2.5-fold less. C10ACP is two carbons longer than C8ACP and the relative
kcat/Km is 20-fold less than C8ACP. C4ACP is four carbons shorter than the natural
substrate and the relative kcat/Km is 50-fold less than C8ACP. C8CoA is missing the
apo-ACP protein and the relative kcat/Km is 5000-fold less than C8ACP. This huge
decrease in catalytic efficiency for C8CoA indicates that ACP binding is important for
substrate recognition and turn over. This data also suggests that the catalytic efficiency is
reduced for alternative acyl-ACPs and can be the kinetic parameter determining
selectivity.
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Table 5.

Effect of acyl-ACP substrates when SAM is fixed on BmaI1 activity
Km µM

kcat/Km (µM-1)(min-1)

kcat/Km Relatived

6±1

0.96 ± 0.18

1.00

1.5 ± 0.1

4±1

0.38 ± 0.10

0.40

SAM-Cl

0.60 ± 0.05

29 ± 2

0.021 ± 0.002

0.02

C10ACPc

SAM-Cl

0.90 ± 0.10

19 ± 4

0.047 ± 0.011

0.05

C8CoA

SAM-Cl

0.11 ± 0.01

541 ± 14

0.0002 ± 0.00001

0.0002

Variable S

Fixed S

kcat (min-1)

C8ACPc

SAM-Cl

5.8 ± 0.6

C6ACPc

SAM-Cl

C4ACPc

c

apo-ACP precipitated, acyl-ACP unprecipitated

d

[{kcat/ Km}/{0.96}]
Table 6 is a compilation of the kinetic parameters measured using fixed substrates

(C4ACP, C6ACP, C10ACP, C8CoA) and varying SAM-Cl. For each acyl-ACP, the Km
is comparable. The kcat, however, decreased for alternative substrates compared to
C8ACP fixed concentrations with variable concentrations of SAM-Cl. The kcat for fixed
concentrations of C8ACP with variable concentrations of SAM-Cl is 5.8 ± 0.6 min-1.
The kcat for fixed C6ACP with variable SAM-Cl is the most similar to C8ACP, followed
by fixed C10ACP and fixed C4ACP with variable SAM-Cl. The alternative substrates
are less active with this observed reduction in kcat for fixed acyl-ACP and variable SAMCl.
The relative catalytic efficiency for all fixed acyl-ACPs and C8CoA were
compared in Table 6. C6ACP is only two carbons shorter than the natural substrate and
the measured kcat/Km was almost identical to C8ACP. C10ACP is two carbons longer
than C8ACP and the relative kcat/Km is 6.3-fold less than C8ACP. C4ACP is four carbons
shorter than the natural substrate and the relative kcat/Km is 5.6-fold less than C8ACP.
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C8CoA is missing the apo-ACP protein and the relative kcat/Km is 20-fold less than
C8ACP. This data also suggests that the catalytic efficiency is reduced for alternative
acyl-ACPs.
Table 6.

Effect of SAM when acyl-ACP substrates are fixed on BmaI1 activity

Variable S

Fixed S

kcat (min-1)

SAM-Cl

C8ACP

5.80 ± 0.60

1.80 ± 0.50

3.22 ± 0.96

1.00

SAM-Cl

C6ACP

1.70 ± 0.10

0.54 ± 0.07

3.17 ± 0.46

0.98

SAM-Cl

C4ACP

1.10 ± 0.20

1.91 ± 0.32

0.58 ± 0.14

0.18

SAM-Cl

C10ACP

0.40 ± 0.03

0.80 ± 0.08

0.50 ± 0.06

0.16

SAM-Cl

C8CoA

0.15 ± 0.01

0.94 ± 0.08

0.16 ± 0.02

0.05

d

Km mM

kcat/ Km (mM-1)(min-1)

kcat/ Km Relatived

[{kcat/ Km}/{3.22}]
Since structural studies have proposed a binding site for ACP with AHL-

synthases, C8CoA was also tested to determine if activity was affected, since it doesn’t
contain the ACP protein. When SAM was fixed, there was a 5000-fold decrease in
catalytic efficiency compared to C8ACP. When C8CoA was fixed, there was a 20-fold
decrease in catalytic activity compared to C8ACP. C8CoA assays have the most drastic
decrease in BmaI1 activity compared to the acyl-ACPs. This implies that binding of the
ACP is essential for optimal activity for BmaI1.

Good Substrates Show Hyperbolic Behavior for Both SAM and acyl-ACP and Poor
Substrates Show Sigmoidal Behavior
Figure 27 and 28 show the Velocity vs. [Substrate] curves generated for variable
acyl-ACPs and C8CoA while SAM is fixed and variable SAM while acyl-ACPs and
C8CoA is fixed. Interestingly, many of these curves are not hyperbolic. Table 5 and 6
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lists the substrate curve types generated from specific conditions. The natural substrate to
BmaI1, C8ACP shows a hyperbolic curve when assayed with DCPIP. C6ACP and
C10ACP also have a hyperbolic curve when assayed with DCPIP. These two substrates
are only 2 carbon chains different from the natural substrate. C4ACP is four carbons
shorter than C8ACP and this substrate shows a sigmoidal curve when assayed with
DCPIP. C8CoA lacks the apo-ACP protein and it too has a sigmoidal curve. Both
sigmoidal curves show positive cooperativity. This data indicates that good substrates
show hyperbolic behavior while poor substrates show sigmoidal behavior.

Good Substrates Show Substrate Inhibition with Fixed SAM
Figure 27 displays the Velocity vs. [Substrate] curves generated for variable acylACPs and C8CoA while SAM is fixed. Substrate inhibition is observed with the natural
substrate to BmaI1, C8ACP as well as with C6ACP. Inhibition is not seen with the other
substrates. This postulates that good substrates like C8ACP and C6ACP show inhibition
when they are varied with fixed SAM-Cl. The above data can be summarized as follows:
1. Good Substrates Show Hyperbolic Behavior for both SAM and acyl-ACP
2. Poor substrates Show Sigmoidal Behavior
3. Good Substrates Show Inhibition with Fixed SAM

Discussion
One objective of the work described in this thesis was to study BmaI1 substrate
preparation effects on activity. Additionally, we explored the effects on BmaI1 activity
using acyl-ACPs with variable acyl chain lengths. Studying BmaI1 with these alternative
substrates provided insight into the kinetic mechanism and helped to understand how this
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enzyme discriminates between specific and nonspecific acyl-ACP substrates.

The

BmaI1 substrate specificity study described is our first step towards understanding how
AHL-synthase enzymes synthesize one abundant signal from the abundant acyl-ACPs
available to achieve QS.

Does precipitation and resuspension affect acyl-ACP activity with BmaI1 AHL-synthase?
Apo-ACP is precipitated using TCA and sodium deoxycholate while C8ACP is
precipitated using acetone. We were interested to check if precipitation and resuspension
of these proteins would affect acyl-ACP activity with BmaI1 AHL-synthase. We found
that precipitating apo-ACP and not precipitating C8ACP with acetone gave the most
active acyl-ACP substrate. ACP is a dynamic protein that interacts in fatty acid
biosynthesis with multiple enzyme domains. These interactions have been shown to cause
conformational changes in the ACP structure that are pertinent for successful synthesis of
acyl-ACPs.42 Ribbon structures and crystallography studies have shown that AHLsynthases have a specific position for ACP to bind in the active site (Fig. 8).38-40 It is not
unreasonable to predict that the conformation of ACP changes during this interaction.
This suggests a specific conformation of ACP is needed during AHL synthesis using
AHL-synthases like BmaI1. If preparation of apo-ACP itself causes a conformational
change in ACP that is not native to the BmaI1 reaction, then the rate of activity could
change. Additionally, the preparation of the acyl-ACP could induce a change in structure
and result in a change in BmaI1 activity. The samples that were both precipitated or
both not precipitated had lower overall rates, which suggest the structure of ACP was
altered from its active conformation during preparation.
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Does BmaI1 activity change with different SAM formulations such as SAM-chloride and
SAM-tosylate?
AHL-synthase structure studies propose a specific binding site for SAM during
catalysis (Fig. 8).38-40 SAM formulations like SAM-Cl and SAM-tosylate contain anionic
salts. These salts may inhibit a chemical or enzymatic step necessary for optimal activity
of BmaI1. I sought to determine if the chloride or tosylate salt influenced the activity of
BmaI1 when coupled with C8ACP. I found that commercially available formulations of
SAM-Cl and SAM-tosylate do not affect Km or kcat measurements of BmaI1. The
catalytic efficiency for SAM-Cl was found to be 3.2 min-1µM compared to SAM-tosylate
at 6.9 min-1µM. This suggests that SAM-tosylate would be the better substrate to
purchase and use when studying BmaI1. However, the curve generated for SAM-tosylate
showed inhibition. This inhibition is due to the tosylate salt and lowers the overall Vmax
observed. Therefore, to avoid complication arising from tosylate inhibition, we preferred
to use SAM-Cl to study BmaI1.

How does acyl-ACP substrate activity change with acyl chain length? How does the
catalytic efficiency of a shorter or longer chain acyl-ACP substrate compare with native
substrate?
BmaI1 utilizes C8ACP and SAM to produce C8HSL. The V-cleft in the active
site accommodates the C8 acyl chain of C8ACP. It is not unreasonable to predict that
shorter and longer acyl chained acyl-ACPs could also ‘fit’ in this V cleft
(Fig. 8). We were interested in studying the effect of variations in acyl chain length on
BmaI1 activity. Except the C6ACP substrate, we found that all alternative acyl-ACPs and
C8CoA had an increase in Km and a decrease in kcat compared to C8ACP. Similar
results were observed when the concentration of SAM was fixed with adding variable
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concentrations of acyl-ACP, as well as when the concentration of the acyl-ACPs were
fixed with adding variable concentrations of SAM-Cl. The true understanding of this
drop in activity is understood when comparing catalytic efficiencies (kcat/Km) for each
substrate with respect to C8ACP.
When studying the effects of alternative substrates on BmaI1 activity, it is clear
that the catalytic efficiency is decreased compared to C8ACP. The most comparable
substrate to C8ACP catalytic efficiency was C6ACP, which was 4-fold less active than
C8ACP. C10ACP was the next more comparable substrate with a 20-fold decrease in
catalytic efficiency. These two substrates are only 2 carbon chains different from the
C8ACP. The next substrate studied was C4ACP, which had a 50-fold decrease in
catalytic efficiency compared to C8ACP. C4ACP is four carbon chains shorter than
C8ACP.
To appreciate how alternative substrates affect BmaI1 activity, it is important to
understand how AHL-synthases interact with acyl-ACP substrates. Unfortunately, there
have been no enzyme-substrate crystal structures for BmaI1 to date. It is known that
when acyl-ACP interacts with other enzymes, the ACP portion docks to a basic residue
patch in the partner enzyme. Then the acyl chain is delivered by means of the
pantetheine linker to the partner enzyme’s active site using a “switch-blade mechanism.”
42,44

Cooperative interactions between the acyl-chain-enzyme and the ACP-enzyme site

help lock the acyl-chain into a productive conformation. A nucleophile then attacks the
carbonyl center of the acyl chain (much like the SAM amine in AHL-synthase reactions)
and the reaction proceeds. The rate of the reaction is dependent on the cooperative
interaction and the nucleophilic attack step.
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It is known that ACP-enzyme interactions are predominantly electrostatic due to
the recognition helix II being negatively charged.44 AHL-synthases like BmaI1 have
residues along alpha-7 and beta-8 that form a positively charged patch on the surface (see
Fig. 8 for description of amino acids involved in ACP binding). It is not unreasonable to
predict that once the acyl chain has been delivered to BmaI1using the panthetheine linker,
then the acyl-chain-BmaI1 and the ACP-BmaI1 complexes will undergo cooperative
interactions. These interactions help to position the acyl-chain into a productive
conformation for the SAM-amine to attack the carbonyl center of the acyl-ACP at the
acylation step. If acyl chain length variations alter the cooperative interactions and/or
inhibit nucleophilic attack, then the activity of BmaI1 would decrease.
When studying the effects of alternative substrates on BmaI1 activity, it is clear
that the catalytic efficiency is decreased compared to C8ACP. The most comparable
substrate to C8ACP catalytic efficiency was C6ACP (Table 5). The hexanoyl side chain
in C6ACP is not that different from the octanoyl side chain in C8ACP. Perhaps the
catalytic efficiency is comparable because the thioester carbonyl of C6ACP could easily
be locked in a productive conformation for SAM amine attack.

The decrease in

catalytic efficiency for C6ACP can possibly be attributed to the slight increase in time it
takes for the acyl chain interaction between enzyme and substrate to successfully lock
and allow nucleophilic attack.
C10ACP was the next more comparable substrate to C8ACP (Table 5). The
decanoyl side chain in C10ACP is only two carbons longer than the octanoyl side chain
in C8ACP. This increase in carbon chain length could possibly make the acyl chain
bulge out of the V-cleft. This puckering would restrict the flexibility of the acyl chain of
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C10ACP and make it difficult to lock it into position for nucleophilic attack.

This

would decrease the rate at which the product is turned over (kcat). The next substrate
studied was C4ACP, which had a 50-fold decrease in catalytic efficiency compared to
C8ACP. C4ACP is four carbon chains shorter than C8ACP. It may also be that a 4carbon shorter acyl-chain has higher degree of freedom in the acyl-chain pocket. The
increase in acyl-chain flexibility would make it difficult to lock the thioester carbonyl
carbon in a productive conformation, conducive for nucleophilic attack by SAM-amine.
This would drastically decrease the rate at which the product is turned over (kcat).
The final substrate to study was C8CoA, which was 5000-fold less active than
C8ACP when used as the variable substrate (Table 5). This drop in catalytic efficiency
suggests the rate of product turnover is negligible compared to C8ACP. C8CoA contains
the appropriate amount of carbon chains and the pantetheine linker portion necessary for
activity but it lacks the ACP. A substrate without the ACP portion could not
electrostatically bind to the positively charged residues in BmaI1. When the substrate
lacks ACP, the conformational changes needed to lock the carbonyl center of C8CoA into
position for nucleophilic attack is nearly impossible.

Does the kinetic mechanism for BmaI1 change between specific and nonspecific
substrates? If this is true, can we get additional insight on how this enzyme discriminates
between specific and nonspecific acyl-ACP substrate?
We have found that the KiA for C8ACP is much less than the Km of SAM-Cl,
which suggest BmaI1 follows an ordered sequential mechanism. We have not done any
product inhibition experiments to confirm this mechanism. However, we have found that
when SAM-Cl was fixed and acyl-ACP was varied the Velocity versus [Substrate] curves
were hyperbolic for C8ACP, C6ACP, and C10ACP and sigmoidal for C4ACP and
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C8CoA (Table 5). When acyl-ACPs were maintained at a fixed concentration and SAMCl was varied, hyperbolic curves were obtained for C8ACP and C6ACP and sigmoidal
for C4ACP, C10ACP, and C8CoA (Table 6).
Hyperbolic curves are generated when enzymes respond linearly to changes in
substrate concentrations when the varied substrate concentration is low. Enzymes that do
not produce hyperbolic curves are non-cooperative and don’t follow Michaelis-Menten
kinetics. Sigmoidal curves are generated when enzymes do not respond to changes in
substrate concentration when the varied substrate concentration is low. This is indicated,
as there is no increase in reaction rate as substrate concentration is increased. Upon
reaching a threshold concentration, a small increase in substrate concentration produces
large changes in initial rate (inflexion region) until the reaction reaches maximal velocity
(Vmax).
Non-hyperbolic rate curves usually indicate a cooperative enzyme. Cooperativity
refers to the observation that binding of the substrate or ligand at one binding site
affects the affinity of other sites for their substrates. Traditionally, cooperativity required
the participation of multiple, spatially distinct binding sites that communicate with
ligand-induced structural rearrangements and/or multimeric enzymes.48 However,
studies have shown that cooperativity can occur in the absence of multiple binding sites
and without macromolecular oligomerization. 48 AHL-synthases like BmaI1 have only
been observed to have one distinct active site (V-cleft) and are monomeric.
Cooperativity for monomeric enzymes with single ligand binding sites was first
theorized 40 years ago.48,49,50 Only a small number of these enzymes have been
discovered, which includes the human enzyme that is involved in glucose homeostasis,
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glucokinase. These monomeric cooperative systems like traditional cooperative systems
have been attributed to slow, substrate induced alterations in enzyme structure. These
alterations prevent substrate binding from reaching equilibrium on the timescale of
catalytic turnover.48,50 Therefore, the ability for alternative substrates to produce
sigmoidal curves requires an understanding of possible enzymatic mechanisms. The data
summarized in the results section can fit at least two mechanistic possibilities.

The Random Sequential Model
The first possible mechanistic model for bisubstrate enzymes is a random
sequential mechanism with one pathway more favored than the other (Fig. 29). This
model requires that the enzymatic reaction be capable of proceeding through a random
ordered mechanism. This model doesn’t rely on enzyme conformational heterogeneity or
slow interconversion rates.48 This model predicts that cooperativity can be observed when
a random sequential kinetic mechanism has a preferred pathway for substrate addition
(Fig. 29). The disfavored pathway can be populated but contributes negligibly to the
steady-state reaction velocity because its existence provides a mechanism where ‘nonproductive’ intermediate can accumulate. The enzyme 3-deoxy-D-arabinoheptulosonate-7-phosphate synthetase from Rhodomicrobium vannielli functions
according to this model.48
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Figure 29.
Random Sequential Mechanism where the Top Pathway is Favored.
The binding of good acyl-ACP substrate follows the top, favored pathway. In this
pathway, EA is the BmaI1-acyl-ACP complex. This pathway produces product at a
higher rate than the bottom-disfavored pathway where SAM-Cl binds first. In the bottom
pathway, EB is the BmaI1.SAM-Cl complex.
The random sequential mechanism where one pathway is favored over the other
can explain the two Velocity versus [Substrate] curve types observed with BmaI1. First,
we can predict the top pathway where acyl-ACP binds to free enzyme E is most
favorable. This is because the KiA for C8ACP was significantly less than the Km for
SAM-Cl. Substrates that produce hyperbolic curves populate the favored pathway. This
could be due to the BmaI1-C8ACP complex (EA) being more stable compared to the
BmaI1.SAM-Cl (EB) complex. The equilibrium favors the formation of EA and thus
increased addition of acyl-ACP substrate show hyperbolic behavior. The EB enzyme
form can convert back to free E and the reaction favorably proceeds with EA form. The
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lower pathway does exist, but the more stable EA complex drives the reaction forward
via the top pathway.
C8ACP is the native substrate and produces a hyperbolic curve. C8ACP,
therefore, populates the favored, more productive pathway and not the ‘lessproductive/non-productive’ pathway because cooperativity isn’t observed (Fig. 27).
When varying acyl-ACPs, good substrates like C8ACP, C6ACP, and even C10ACP
populate the top productive pathway even at low concentrations (Table 5). When SAMCl is varied, hyperbolic behavior is observed with C8ACP and C6ACP.

For both

variable situations, hyperbolic curves result for these substrates because there is not
enough free enzyme (E) to form the EB complex. SAM-Cl then binds to the EA form to
move the reaction favorably forward.
Poor substrates, like C4ACP and C8CoA (whether fixing SAM or using variable
concentrations), cannot populate the top pathway at below threshold concentrations. This
could be because these substrates may produce a less stable EA complex and convert
back to free E. When SAM is in excess compared to acyl-ACP, free E converts to EB. A
significant portion of the enzyme would then exist in the EB form. The EB form is in
abundance compared to free enzyme and, so, successive addition of acyl-ACP favors
BmaI1.SAM-Cl.acyl-ACP form. This disfavored pathway contributes negligibly to the
steady-state reaction velocity and a lag phase in the Velocity versus [Substrate] curve is
observed. This pathway can also become abortive with the accumulation of a ‘nonproductive’ complex like BmaI1.SAM-Cl-acyl-ACP. Abortive complexes do not react
further to produce product. The rise in the sigmoidal curve occurs when an increase in
acyl-ACP concentration drives BmaI1.SAM.acyl-ACP complex back to free enzyme E
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(Table 5 and Fig. 27). Since there is an abundance of E, the chances for poor substrates to
bind to free enzyme increases. The top pathway will then be populated.
Additional support for this mechanism is seen with the substrate inhibition data
(Table 5). The data collected suggests that good substrates show substrate inhibition only
when using variable concentrations of acyl-ACPs. This can be attributed to the random
sequential model where substrate addition favors one pathway. We discussed that good
substrates populate the favored pathway where acyl-ACP binds first followed by SAMCl. However, good substrates can also bind to E.SAM complex and form E.SAM.acylACP populating the disfavored pathway, albeit to a smaller extent. Why is substrate
inhibition more pronounced beyond saturation? Perhaps, there is too much acyl-ACP
substrate around that binds to E.SAM, pushing the reaction more and more towards
disfavored pathway. Since this pathway has either a lower turnover rate or is abortive, a
decrease in rate is observed. Poor substrates cannot stabilize the EA form until large
concentrations are added. Therefore, at low acyl-ACP concentrations, the less favored
pathway is populated because most of the enzyme is in E.SAM form. At high
concentrations of poor acyl-ACP substrates, the favored pathway is populated. Substrate
inhibition is further evidence that the mechanism is random sequential where one
pathway is favored and the other is disfavored.

Multiple Free Enzyme Form Model
Sigmoidal curves can result from monomeric enzymes that do not follow the
random sequential mechanism with a favored pathway. One such model that attests for
monomeric cooperativity is known as the mnemonic model. This model proposes that
the conformation of an enzyme following product release can be different from the initial
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enzyme state. This requires an oscillation between two enzyme species, a low-affinity
conformation (E*) and a high-affinity conformation (E) (Fig. 30A).

Figure 30.
Multiple Free Enzyme Form Models. The mnemonic model (A),
substrate induced enzyme transition model (B) and the ligand-induced slow transition
model (C) require the slow interconversion between two enzyme conformations, a lowaffinity (E*) in red and a high-affinity (E) in blue.
For the model to produce positive cooperativity (like observed with our data), the
E* species dominates in the absence of substrate. E* to E conversion must be slow. When
substrate bind to the less active E* form, conformational transitions occur to release
product and to generate the high-affinity enzyme species, E. When substrate is in excess,
the high-affinity enzyme form, E, does not have time to ‘relax’ to the low-affinity form,
E*. The enzyme can rapidly bind another molecule of substrate for additional rounds of
catalysis. This results in a hyperbolic curve. If substrate is at low concentrations, then E
can ‘relax’ and form E* again. Since E* is the low affinity enzyme form, the curve will
look sigmoidal at these low concentrations. 48,50 This model would result in sigmoidal
curves for all substrates due to the initially slow transition from E* to E via substrate
addition.
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An alternative model where substrate addition converts the active enzyme ES
complex to a less active E*S complex should also be considered (Fig. 30B; Substrate
Induced Enzyme Transition).51 Both of these forms can convert substrate to product and
results in the release of two enzyme forms, E and E*. Additionally, breakdown of the
E*S complex generates free enzyme E*. This less active free enzyme form can react
with substrate leading to further turnover or spontaneously revert to the more stable
enzyme form, E.51
An additional model that could describe monomeric cooperativity is known as the
Ligand-Induced Slow Transition (LIST) model (Fig. 30C).48 The LIST model is similar
to the mnemonic model in that two enzyme species exists, E* and E. These two species
also possess different affinities for substrate. However, the LIST model assumes that
without substrate both enzyme forms are in a pre-existing equilibrium. The LIST model
also assumes interconversion between these two forms occurs slower than product
formation. This prevents equilibration when substrate is associating. This slow step can
be due to isomerization or an association-dissociation process. Both conformations are
catalytically active, and the steady-state velocity is therefore dependent on the sum of
these two catalytic cycle’s rates. However, in order to support a multiple free enzyme
model, there must be evidence that the enzyme exists in two forms. Structural and presteady state kinetics are needed to verify the existence of both enzyme species. Structural
studies on acyl-ACP in complex with BmaI1 are in progress.
Both random sequential and multiple free enzyme form models assume the
existence of two enzyme forms: the more active E and less active E.* or E.SAM
complex. The acyl-ACPs can bind to either form. Considering these models with the data

73
obtained, the addition of good substrates like C8ACP, C6ACP, and even C10ACP shift
the equilibrium between these two enzymes species to the more active BmaI1 form. The
more active enzyme would have a higher rate of turnover and a hyperbolic curve should
be observed.
Burkart and co-workers observed that when ACP binds to enzymes the acyl chain
is released to the acyl chain pocket in the partner enzyme.52 Perhaps these poor substrates
with nonspecific acyl chains do not fit well in the acyl chain pocket (V-cleft) of BmaI1.
This lack of fit could revert the chain back to being sequestered into the ACP, which
could make BmaI1.acyl-ACP complex less stable. In addition, for nonspecific substrates,
the Enzyme.acyl-ACP complex may also be less productive. Therefore, a nonspecific
acyl-ACP substrate could result in a less stable and less productive BmaI1.acyl-ACP
complex thereby keeping the AHL-synthase rates low compared to the native acyl-ACP
substrate. Our results also suggest that both binding and catalytic steps are affected when
a nonspecific acyl-ACP substrate binds to BmaI1 AHL synthase. It is now clear that
native acyl-ACP substrate recognition occurs at more than one step during AHL
synthesis.

Conclusion

This thesis work is the first study to report differences in rates and mechanism for
nonspecific acyl-ACP substrate reacting with an AHL-synthase.
When studying BmaI1, we observed that the method of preparation of apo-ACP
and the acyl-ACP is important to achieve optimum activity. SAM-Cl and SAM-tosylate
do not affect BmaI1 optimum activity. Therefore, either substrate can be used to study
AHL synthase. We found that catalytic efficiency for nonspecific acyl-ACP substrate is
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drastically low compared to C8ACP. This decrease in activity explains tight signal
specificity in bacterial QS, in vivo. The kinetic mechanism suggests a random sequential
mechanism where one pathway (acyl-ACP binding first to the free enzyme) is favored
over the other pathway (SAM binding first to the free enzyme). Our data suggest that
acyl-ACP substrate can bind to at least two enzyme forms. The formation of a stable and
productive E.acyl-ACP complex is critical in AHL synthesis. Based on our data with
alternative substrates, we infer that the E.acyl-ACP complex is less stable and less
productive for nonspecific acyl-ACP substrates. Finally, acyl-ACP substrate recognition
occurs at multiple steps in AHL synthesis.
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